Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eperisone hydrochloride + diclofenac sodium is a fixed-dose combination of two pharmaceutical agents used primarily for the management of acute musculoskeletal pain and muscle spasms, especially in conditions such as low back pain. Eperisone is a centrally acting muscle relaxant (antispasmodic) that works by relaxing skeletal muscles and vascular smooth muscles, reducing myotonia, improving blood circulation, and suppressing the pain reflex. Its mechanism involves inhibition of neural activity and pain sensation by blocking voltage-gated sodium channels in the brain stem[3][7]. Diclofenac sodium is a non-steroidal anti-inflammatory drug (NSAID) that exerts its effect mainly through inhibition of cyclooxygenase (COX), thereby reducing prostaglandin synthesis responsible for inflammation and pain[1][2][6]. The combination provides synergistic relief from both muscle spasm-related stiffness and inflammatory pain. This product is not approved in all countries but is widely available in India and other Asian markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Eperisone hydrochloride + diclofenac sodium.